CN104939843A - Implanted cancer relapse real-time monitoring system - Google Patents
Implanted cancer relapse real-time monitoring system Download PDFInfo
- Publication number
- CN104939843A CN104939843A CN201510406415.3A CN201510406415A CN104939843A CN 104939843 A CN104939843 A CN 104939843A CN 201510406415 A CN201510406415 A CN 201510406415A CN 104939843 A CN104939843 A CN 104939843A
- Authority
- CN
- China
- Prior art keywords
- circulation
- rna
- monitoring system
- free
- wireless communication
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 124
- 201000011510 cancer Diseases 0.000 title claims abstract description 115
- 238000012544 monitoring process Methods 0.000 title claims abstract description 79
- 238000004891 communication Methods 0.000 claims description 51
- 230000005611 electricity Effects 0.000 claims description 28
- 238000009396 hybridization Methods 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 230000001939 inductive effect Effects 0.000 claims description 20
- 239000000523 sample Substances 0.000 claims description 20
- 230000000284 resting effect Effects 0.000 claims description 17
- 238000012545 processing Methods 0.000 claims description 13
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 11
- 230000005059 dormancy Effects 0.000 claims description 11
- 239000002070 nanowire Substances 0.000 claims description 11
- 229910052710 silicon Inorganic materials 0.000 claims description 11
- 239000010703 silicon Substances 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 10
- 230000009870 specific binding Effects 0.000 claims description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 4
- 238000004020 luminiscence type Methods 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 239000012530 fluid Substances 0.000 abstract description 15
- 150000007523 nucleic acids Chemical class 0.000 abstract description 9
- 108020004707 nucleic acids Proteins 0.000 abstract description 8
- 102000039446 nucleic acids Human genes 0.000 abstract description 8
- 238000000338 in vitro Methods 0.000 abstract description 6
- 238000012546 transfer Methods 0.000 abstract description 4
- 239000003147 molecular marker Substances 0.000 abstract description 2
- 238000002513 implantation Methods 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 230000005540 biological transmission Effects 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 193
- 108020004999 messenger RNA Proteins 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 108091070501 miRNA Proteins 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 239000002679 microRNA Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000001338 self-assembly Methods 0.000 description 5
- 239000004065 semiconductor Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000006884 silylation reaction Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 102000003910 Cyclin D Human genes 0.000 description 3
- 108090000259 Cyclin D Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108091033773 MiR-155 Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 108091028049 Mir-221 microRNA Proteins 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108091064399 miR-10b stem-loop Proteins 0.000 description 1
- 108091091360 miR-125b stem-loop Proteins 0.000 description 1
- 108091058688 miR-141 stem-loop Proteins 0.000 description 1
- 108091045665 miR-202 stem-loop Proteins 0.000 description 1
- 108091062762 miR-21 stem-loop Proteins 0.000 description 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 1
- 108091061917 miR-221 stem-loop Proteins 0.000 description 1
- 108091063489 miR-221-1 stem-loop Proteins 0.000 description 1
- 108091055391 miR-221-2 stem-loop Proteins 0.000 description 1
- 108091031076 miR-221-3 stem-loop Proteins 0.000 description 1
- 108091050195 miR-302b stem-loop Proteins 0.000 description 1
- 108091029119 miR-34a stem-loop Proteins 0.000 description 1
- 108091090987 miR-425 stem-loop Proteins 0.000 description 1
- 108091034121 miR-92a stem-loop Proteins 0.000 description 1
- 108091041519 miR-92a-3 stem-loop Proteins 0.000 description 1
- -1 mitDNA) Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1473—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6813—Specially adapted to be attached to a specific body part
- A61B5/6824—Arm or wrist
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/742—Details of notification to user or communication with user or patient ; user input means using visual displays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/7455—Details of notification to user or communication with user or patient ; user input means characterised by tactile indication, e.g. vibration or electrical stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
Abstract
The invention discloses an implanted cancer relapse real-time monitoring system. The monitoring system comprises an in-vivo implantation assembly and an in-vitro assembly, wherein the in-vivo implantation assembly can convert concentration information of circulating cell-free nucleic acids in a tissue fluid into transmittal digital information and transmit the digital information to the in-vitro assembly in a wireless transmission manner; the in-vitro assembly analyzes the received circulating cell-free nucleic acid information and informs a user of the implanted cancer relapse real-time monitoring system of paying attention to cancer relapse danger in an information display or warning manner. The implanted cancer relapse real-time monitoring system can monitor a molecular marker, circulating cell-free nucleic acids, of cancer relapse/transfer in real time and can detect the cancer relapse danger in an early stage of cancer relapse, so that a patient suffering from cancer relapse can be treated in time.
Description
Technical field
The invention belongs to medical instruments field, relate to a kind of cancer return monitoring system, be specifically related to a kind of implanted cancer return real-time monitoring system.
Background technology
The curative competence of current China cancer is also not fully up to expectations, and in whole cancer patient, nearly 1/3 can be cured, and obtains the chance of long term survival, but also has the cancer patient about half to occur relapse and metastasis in the course of disease.Cancer return refers to that the cancer be brought under control occurs again on former hair device official, or cancer invades lymph vessels or body cavity from original site, moves to elsewhere continued growth, forms the tumor with primary tumor same-type.Some cancer can first treatment after some months or recur after several years.Therefore for cancer patient, the monitoring carrying out postoperative recurrence transfer is very important.The sign of cancer return transfer find more early, just can take counter-measure in time, the probability that effective suppression cancer return shifts, the life cycle that prolongation cancer patient is postoperative.
The free RNA (circulating cell-free nucleic acids) of circulation refers to and is present in human recycle system, be free on extracellular micro-endogenous or Exogenous Nucleic Acid fragment, comprise core DNA, mitochondrial DNA (mitochondrial DNA, mitDNA), viral DNA, messenger RNA (messenger RNA, and Microrna (microRNA, circulation free RNA) etc. mRNA).The stability of mRNA itself is lower, and the RNA enzyme level simultaneously in tumor patient blood raises, and therefore previously think that circulation free mRNA degradation speed is very fast, clinical value is limited.Have research to be disclosed in the serum of tumor patient, RNA exists with the form of fat egg from complex.Separately studies have found that, free mRNA multi-source, in apoptosis, is present in apoptotic body, and the free mRNA stability therefore in tumor patient blood is higher.These features all make free mRNA detect to be applied to and clinically become possibility.Research finds, can detect that the overall survival of the patient of cyclin D 1mRNA is starkly lower than the patient of blood plasma cyclin D1mRNA feminine gender in the blood plasma of patient with breast cancer; In the good patient of clinical pathologic characteristic prompting prognosis, the patient's prognosis detecting cyclin D 1mRNA in blood plasma is poor; In the patient of his silent former times sweet smell treatment, the overall survival of the patient of the blood plasma cyclin D 1mRNA positive is starkly lower than the patient of cyclin D1mRNA feminine gender.In addition, research finds that plasma of patients with nasopharyngeal carcinoma mRNA integrity reduces, and after radiotherapy, plasma free mRNA integrity obviously rises, and the free mRNA level of rising can be used as the index of disease amelioration.Above-mentioned achievement in research shows that mRNA free in blood can become the molecular marker of early diagnosis of cancer, relapse and metastasis monitoring.
MiRNA has important function in gene expression, post-transcriptional control, and may play the effect of proto-oncogene or antioncogene.They have high stability in plasma or serum, and with the generation of tumor, develop closely related, these speciality free RNA that makes to circulate becomes a kind of potential tumor markers.In kinds of tumors blood samples of patients, having found the abnormal change of the free rna level of circulation at present.MiR-155, miR-202, miR-425, miR-302b and miR-125b etc. are that expressing in healthy population and plasma of breast cancer patients or serum of reporting in recent years has the circulation of notable difference to dissociate RNA, in the early screening of breast carcinoma, have potential value; In addition, the level of miR-115 in hormone-sensitive and the insensitive blood serum of patients with human breast carcinoma of hormone is variant, and miR-10b level in the patients serum of estrogen receptor negative raises.For colorectal cancer patients, during miR-92a detects in early days, embody higher sensitivity; The rising of miR-21, the reduction of miR34a also have higher diagnosis effect; MiR-141 with miR-221 is then considered to relevant to poor prognosis.
The mode of current patient monitoring cancer return mainly regularly arrives hospital and checks, and this mode is for patient, and one is inconvenient, and expend time in, two is check not in time, likely misses the probability of early discovery cancer return.Conveniently cancer patient can check oneself the recurrence of cancer timely, study a kind of can Real-Time Monitoring cancer patient recurrence equipment be necessary.
Prior art to show in blood that the free circulation RNA that dissociates can be used as the potential source biomolecule label detecting all kinds of cancer and disease, for the earlier detection of patient's peripheral blood cancer and the detection of cancer return.Tissue fluid is that blood plasma filters from capillary wall and formed, and except not containing except macro-molecular protein, other composition is basic identical with blood plasma.Therefore the free circulation existed in the blood RNA that dissociates exists equally in tissue fluid, and namely the level therefore by detecting the free RNA of free circulation in tissue fluid can be used for the earlier detection of cancer and the detection of cancer return, acts on same blood the same.
Advantage of the present invention and beneficial effect:
1, whether implanted cancer return real-time monitoring system of the present invention is judged that cancer patient is postoperative recurred by the circulation detected in the tissue fluid rna level that dissociates, the diagnosis of molecular level can be able to find in early days in recurrence, provides diagnostic base for taking corresponding treatment means effectively and timely.
2, implanted cancer return real-time monitoring system of the present invention can realize monitoring anywhere or anytime, reaches the object of real-time dynamic monitoring, and cancer patient can be made to grasp the current intelligence of cancer return transfer easily timely.
3, implanted cancer return real-time monitoring system of the present invention is a monitoring system that can reuse, this monitoring system realizes the unlatching of monitoring system or the switching of resting state by the dissociate charging property of RNA sensor of controlled circulation, avoids the operation often detecting and once need again to implant monitoring system afterwards.
Summary of the invention
In order to solve the deficiencies in the prior art, the object of the present invention is to provide a kind of implanted cancer return real-time monitoring system, described monitoring system completes the monitoring to cancer return by the level of the free RNA of circulation in monitoring skin undertissue liquid.Described monitoring system arranges the threshold value of a free RNA of circulation, when the circulation detected dissociate the level of RNA reach or exceed this threshold value time, described monitoring system then can notify by the mode given the alarm that monitoring system wearer cancer return may occur, cancer patient just can arrive hospital in time and make a definite diagnosis, and enables the state of an illness obtain control early.
To achieve these goals, this invention takes following technical scheme:
The invention provides a kind of implanted cancer return real-time monitoring system, described cancer return real-time monitoring system comprises et al. Ke assembly 1 and external assembly 2, described et al. Ke assembly 1 comprises circulation free RNA sensor 11, data processing module 12, first wireless communication module 13, described data processing module 12 comprises input interface 121, microprocessor 122, output interface 123, reactor 124, described input interface 121 receive described circulation dissociate RNA sensor 11 export electrochemical signals and input described microprocessor 122 after it is converted into digital signal, be uploaded to described external assembly 2 by described output interface 123 via described first wireless communication module 13 after described microprocessor 122 pairs of digital signals carry out protocol conversion, described external assembly 2 comprises data receiver 21, and described data receiver 21 comprises controller 211, display 212, siren 213, second wireless communication module 214, described controller 211 receives and analyzes circulation that described et al. Ke assembly 1 uploads and to dissociate RNA signal, afterwards free for circulation RNA information is sent on described display 212 and shows, the analysis programme of described controller 211 arranges a threshold value, when this threshold value of horizontal exceeding of the free RNA that circulates, described controller 211 sends instruction to described siren 213, described siren 213 gives the alarm, notify that wearer notes the danger of cancer return, the control command of described controller 211 passes on the described reactor 124 in described et al. Ke assembly 1 by described second wireless communication module 214, described reactor 124 controls described circulation and to dissociate the unlatching of RNA sensor 11 or resting state, when described circulation dissociates 11 dormancy of RNA sensor, the free RNA sensor 11 of circulation is with negative electricity, association reaction is there is not with the RNA that dissociates of the circulation with negative electricity, when described circulation dissociate RNA sensor 11 open time, the described circulation RNA sensor 11 that dissociates is not charged, association reaction is there is with the RNA that dissociates of the circulation with negative electricity, the electronegative circulation RNA that dissociates causes the dissociate electrical conductivity of RNA sensor 11 of described circulation to change, thus the concentration information of free for circulation RNA is converted into electrochemical signals.
Further, described external assembly 2 also comprises intelligent mobile terminal equipment 22, described data receiver 21 also comprises the 3rd wireless communication module 215, and free for circulation RNA information is sent in described intelligent mobile terminal equipment 22 by described 3rd wireless communication module 215 by described controller 211.
Described intelligent mobile terminal equipment 22 can be smart mobile phone, flat board or computer.
Further, described siren 213 is vibrators, notifies that wearer notes the danger of cancer return by the mode of vibration.
Further, described siren 213 is luminous organs, notifies that wearer notes the danger of cancer return by the mode of luminescence.
Further, the described circulation RNA sensor 11 that dissociates comprises circulation free RNA trapping layer 111, hybridization signal inductive layer 112.Described circulation RNA trapping layer 111 of dissociating sticks on described hybridization signal inductive layer 112.Described circulation RNA trapping layer 111 of dissociating is made up of the capture probe with the free RNA specific binding of circulation.
The present invention use with the capture probe of the free RNA specific binding of circulation can be DNA, RNA, peptide nucleic acid(PNA) or lock nucleic acid, as long as this probe can to dissociate RNA specific binding with circulation.Circulation for known array dissociates RNA, and the capture probe that those skilled in the art are hybridized with it according to the free RNA sequential design of circulation is routine techniques.Preferably, described capture probe is peptide nucleic acid(PNA) (PNA).
The nucleic acid analog of PNA to be a class with many phthaleins amine chain replace ribose (or deoxyribose) phosphate backbone, have Stability Analysis of Structures, not by nuclease and proteasome degradation, can the feature such as, electric neutrality low with base complementrity mode and single nucleic acid strands, cytotoxicity.PNA and DNA, RNA have stronger adhesion, have good specificity and higher sensitivity, and make PNA-DNA due to its electroneutral character, the double-strand of PNA-RNA is more stable, as compared to corresponding DNA-DNA, DNA-RNA double-strand, there is higher melting temperature.Due to the structural stability of PNA, make it can in number of chemical reagent stable existence, can stably be present in the wider temperature range of sour environment neutralization.Therefore, in the molecular hybridization that PNA can be widely used in pathogen, heredopathia detects, in situ hybridization, mutation analysis, anticancer, antiviral antisense nucleic acids research and application.
Further, described hybridization signal inductive layer 112 comprises by silicon nanowire array.Described hybridization signal inductive layer 112 is on the silicon nanowires utilizing conventional semiconductors technology to process, and is prepared from by silylation modification, surperficial unimolecule rete self assembly operation, fixes can form described circulation and to dissociate RNA sensor through capture probe.The preparation process of the free RNA sensor of circulation is well known to those skilled in the art.
Further, described first wireless communication module 13, described second wireless communication module 214, described 3rd wireless communication module 215 adopt any one in Bluetooth protocol or Zigbee protocol.
Further, described data receiver 12 can be worn at any part on cancer patient's health, is preferably worn in wrist.In addition, described data receiver 12 also can not be worn on a certain position of health of cancer patient, but uses as in vitro accessory.
Further, described controller 211 timing realizes the free unlatching of RNA sensor of circulation or the control of dormancy.The interval time of continuously adjustabe between 1s to 1800s that control command is assigned, adjustment stepping is 2s.
The dissociate kind of RNA of circulation used in the present invention is that the circulation that there is significant correlation between those and cancer to be detected dissociates RNA, and the concentration namely by detecting the free RNA of circulation can judge whether whether cancer recurs.The free RNA of circulation comprises circulation free mRNA, the free miRNA of circulation.
Preferably, the free RNA of circulation is the free miRNA of circulation.
The using method of implanted cancer return real-time monitoring system of the present invention:
First, control described implanted cancer return real-time monitoring system by described controller 211 and be in resting state, et al. Ke assembly, with negative electricity (institute is electrically charged atomic weak, can not damage human body), is implanted subcutaneous by the free RNA sensor 11 of now circulation;
Secondly, open described implanted cancer return real-time monitoring system by described controller 211, make the circulation RNA sensor 11 that dissociates not charged, the RNA that dissociates of the circulation now in tissue fluid can be combined with the free RNA sensor 11 of circulation;
Finally, after reaction certain hour, close implanted cancer return real-time monitoring system by described controller 211 to make it again to be in resting state, the free RNA sensor 11 of now circulation is with negative electricity, the circulation combined with circulation free RNA sensor 11 in tissue fluid RNA and the circulation RNA sensor 11 that dissociates that dissociates is separated, and described implanted cancer return real-time monitoring system is that detection is next time ready.
Cancer patient is dissociated by the circulation on observation display 212 reaction of RNA information and siren 213, knows whether cancer recurs.
Accompanying drawing explanation
Fig. 1 shows a kind of structural representation of implanted cancer return real-time monitoring system of the present invention;
Fig. 2 shows a kind of structural representation of implanted cancer return real-time monitoring system of the present invention;
Fig. 3 shows circulation of the present invention and to dissociate the structural representation of RNA sensor;
Wherein, 1: et al. Ke assembly; 11: the free RNA sensor of circulation; 111: the free RNA trapping layer of circulation; 112: hybridization signal inductive layer; 12: data processing module; 121: input interface; 122: microprocessor; 123: output interface; 124: reactor; 13: the first wireless communication modules; 2: external assembly; 21: data receiver; 211: controller; 212: display; 213: siren; 214: the second wireless communication modules; 215: the three wireless communication modules; 22: intelligent mobile terminal equipment.
Detailed description of the invention
Below in conjunction with specific embodiment, illustrate the present invention further.Should be understood that these embodiments are only not used in for illustration of the present invention to limit the scope of the invention.
Embodiment 1 one kinds of implanted cancer return real-time monitoring systems
A kind of implanted cancer return real-time monitoring system, cancer return real-time monitoring system comprises et al. Ke assembly 1 and external assembly 2, et al. Ke assembly 1 comprises circulation free RNA sensor 11, data processing module 12, first wireless communication module 13, data processing module 12 comprises input interface 121, microprocessor 122, output interface 123, reactor 124, input interface 121 receives electrochemical signals that the free RNA sensor 11 of circulation exports and input microprocessor 122 after it being converted into digital signal, is uploaded to external assembly 2 after microprocessor 122 pairs of digital signals carry out protocol conversion by output interface 123 via the first wireless communication module 13, external assembly 2 comprises data receiver 21, and data receiver 21 comprises controller 211, display 212, siren 213, second wireless communication module 214, controller 211 receives and analyzing body is implanted into circulation that assembly 1 uploads dissociates RNA signal, afterwards free for circulation RNA information is sent on display 212 and shows, the analysis programme of controller 211 arranges a threshold value, when this threshold value of horizontal exceeding of the free RNA that circulates, controller 211 sends instruction to described siren 213, siren 213 gives the alarm, notify that wearer notes the danger of cancer return, the control command of controller 211 passes on the reactor 124 in et al. Ke assembly 1 by the second wireless communication module 214, reactor 124 controlled circulation dissociates the unlatching of RNA sensor 11 or resting state, when dissociating 11 dormancy of RNA sensor when circulating, the free RNA sensor of circulation is with negative electricity, association reaction is there is not with the RNA that dissociates of the circulation with negative electricity, when the free RNA sensor 11 that circulates is opened, the free RNA sensor 11 of circulation is not charged, association reaction is there is with the RNA that dissociates of the circulation with negative electricity, electronegative circulation RNA cause the circulating electrical conductivity of free RNA sensor 11 of dissociating changes, thus the concentration information of free for circulation RNA is converted into electrochemical signals.
Siren 213 is vibrators, notifies that wearer notes the danger of cancer return by the mode of vibration.
The described circulation RNA sensor 11 that dissociates comprises circulation free RNA trapping layer 111, hybridization signal inductive layer 112.Described circulation RNA trapping layer 111 of dissociating is made up of the capture probe with the free RNA specific binding of circulation.Capture probe is peptide nucleic acid(PNA) (PNA).
Hybridization signal inductive layer 112 comprises silicon nanowire array.Hybridization signal inductive layer 112 is on the silicon nanowires utilizing conventional semiconductors technology to process, and is prepared from by silylation modification, surperficial unimolecule rete self assembly operation, fixes to form the free RNA sensor 11 of circulation through capture probe.The preparation process of the free RNA sensor 11 of circulation is well known to those skilled in the art.
First wireless communication module 13, second wireless communication module 214 adopts Bluetooth protocol.
Data receiver 12 can be worn at any part on cancer patient's health, such as, be worn in wrist.
Controller 211 timing realizes the free unlatching of RNA sensor of circulation or the control of dormancy.The interval time of continuously adjustabe between 1s to 1800s that control command is assigned, adjustment stepping is 2s.
Circulation in the present embodiment RNA that dissociates refers to miRNA.
The using method of above-mentioned implanted cancer return real-time monitoring system:
1, control implanted cancer return real-time monitoring system by controller 211 and be in resting state, et al. Ke assembly, with negative electricity (institute is electrically charged atomic weak, can not damage human body), is implanted subcutaneous by the free RNA sensor 11 of now circulation;
2, open implanted cancer return real-time monitoring system by controller 211, make the circulation RNA sensor 11 that dissociates not charged, the RNA that dissociates of the circulation now in tissue fluid can be combined with the free RNA sensor 11 of circulation;
3, after reacting certain hour, close implanted cancer return real-time monitoring system by controller 211 to make it again to be in resting state, the free RNA sensor 11 of now circulation is with negative electricity, the circulation combined with circulation free RNA sensor 11 in tissue fluid RNA and the circulation RNA sensor 11 that dissociates that dissociates is separated, and implanted cancer return real-time monitoring system is that detection is next time ready.
Whether 4, vibrated by dissociate RNA information and siren of the circulation of display on observation display 212, cancer patient knows whether cancer recurs.
Embodiment 2 one kinds of implanted cancer return real-time monitoring systems
A kind of implanted cancer return real-time monitoring system, cancer return real-time monitoring system comprises et al. Ke assembly 1 and external assembly 2, et al. Ke assembly 1 comprises circulation free RNA sensor 11, data processing module 12, first wireless communication module 13, data processing module 12 comprises input interface 121, microprocessor 122, output interface 123, reactor 124, input interface 121 receives electrochemical signals that the free RNA sensor 11 of circulation exports and input microprocessor 122 after it being converted into digital signal, is uploaded to external assembly 2 after microprocessor 122 pairs of digital signals carry out protocol conversion by output interface 123 via the first wireless communication module 13, external assembly 2 comprises data receiver 21, and data receiver 21 comprises controller 211, display 212, siren 213, second wireless communication module 214, controller 211 receives and analyzing body is implanted into circulation that assembly 1 uploads dissociates RNA signal, afterwards free for circulation RNA information is sent on display 212 and shows, the analysis programme of controller 211 arranges a threshold value, when this threshold value of horizontal exceeding of the free RNA that circulates, controller 211 sends instruction to described siren 213, siren 213 gives the alarm, notify that wearer notes the danger of cancer return, the control command of controller 211 passes on the reactor 124 in et al. Ke assembly 1 by the second wireless communication module 214, reactor 124 controlled circulation dissociates the unlatching of RNA sensor 11 or resting state, when dissociating 11 dormancy of RNA sensor when circulating, the free RNA sensor 11 of circulation is with negative electricity, association reaction is there is not with the RNA that dissociates of the circulation with negative electricity, when the free RNA sensor 11 that circulates is opened, the free RNA sensor 11 of circulation is not charged, association reaction is there is with the RNA that dissociates of the circulation with negative electricity, electronegative circulation RNA cause the circulating electrical conductivity of free RNA sensor 11 of dissociating changes, thus the concentration information of free for circulation RNA is converted into electrochemical signals.
Siren 213 is luminous organs, notifies that wearer notes the danger of cancer return by the mode of luminescence.
The described circulation RNA sensor 11 that dissociates comprises circulation free RNA trapping layer 111, hybridization signal inductive layer 112.Described circulation RNA trapping layer 111 of dissociating is made up of the capture probe with the free RNA specific binding of circulation.Capture probe is peptide nucleic acid(PNA) (PNA).
Hybridization signal inductive layer 112 comprises silicon nanowire array and forms.Hybridization signal inductive layer 112 is on the silicon nanowires utilizing conventional semiconductors technology to process, and is prepared from by silylation modification, surperficial unimolecule rete self assembly operation, fixes to form the free RNA sensor 11 of circulation through capture probe.The preparation process of the free RNA sensor 11 of circulation is well known to those skilled in the art.
First wireless communication module 13, second wireless communication module 214 adopts Zigbee protocol.
Data receiver 12 uses as in vitro accessory.
Controller 211 timing realizes the free unlatching of RNA sensor 11 of circulation or the control of dormancy.The interval time of continuously adjustabe between 1s to 1800s that control command is assigned, adjustment stepping is 2s.
Circulation in the present embodiment RNA that dissociates refers to circulation free mRNA.
The using method of above-mentioned implanted cancer return real-time monitoring system:
1, control implanted cancer return real-time monitoring system by controller 211 and be in resting state, et al. Ke assembly, with negative electricity (institute is electrically charged atomic weak, can not damage human body), is implanted subcutaneous by the free RNA sensor 11 of now circulation;
2, open implanted cancer return real-time monitoring system by controller 211, make the circulation RNA sensor 11 that dissociates not charged, the RNA that dissociates of the circulation now in tissue fluid can be combined with the free RNA sensor 11 of circulation;
3, after reacting certain hour, close implanted cancer return real-time monitoring system by controller 211 to make it again to be in resting state, the free RNA sensor 11 of now circulation is with negative electricity, the circulation combined with circulation free RNA sensor 11 in tissue fluid RNA and the circulation RNA sensor 11 that dissociates that dissociates is separated, and implanted cancer return real-time monitoring system is that detection is next time ready.
4, by observation display 212 display circulation dissociate RNA information and siren whether luminous, cancer patient knows whether cancer recurs.
Embodiment 3 one kinds of implanted cancer return real-time monitoring systems
A kind of implanted cancer return real-time monitoring system, cancer return real-time monitoring system comprises et al. Ke assembly 1 and external assembly 2, et al. Ke assembly 1 comprises circulation free RNA sensor 11, data processing module 12, first wireless communication module 13, data processing module 12 comprises input interface 121, microprocessor 122, output interface 123, reactor 124, input interface 121 receives electrochemical signals that the free RNA sensor 11 of circulation exports and input microprocessor 122 after it being converted into digital signal, is uploaded to external assembly 2 after microprocessor 122 pairs of digital signals carry out protocol conversion by output interface 123 via the first wireless communication module 13, external assembly 2 comprises data receiver 21, intelligent mobile terminal equipment 22, data receiver 21 comprises controller 211, display 212, siren 213, second wireless communication module 214, the 3rd wireless communication module 215, controller 211 receives and analyzing body is implanted into circulation that assembly 1 uploads dissociates RNA signal, afterwards free for circulation RNA information is sent on display 212 and shows, the analysis programme of controller 211 arranges a threshold value, when this threshold value of horizontal exceeding of the free RNA that circulates, controller 211 sends instruction to described siren 213, siren 213 gives the alarm, notify that wearer notes the danger of cancer return, the control command of controller 211 passes on the reactor 124 in et al. Ke assembly 1 by the second wireless communication module 214, reactor 124 controlled circulation dissociates the unlatching of RNA sensor 11 or resting state, when dissociating 11 dormancy of RNA sensor when circulating, the free RNA sensor of circulation is with negative electricity, association reaction is there is not with the RNA that dissociates of the circulation with negative electricity, when the free RNA sensor 11 that circulates is opened, the free RNA sensor of circulation is not charged, association reaction is there is with the RNA that dissociates of the circulation with negative electricity, electronegative circulation RNA cause the circulating electrical conductivity of free RNA sensor of dissociating changes, thus the concentration information of free for circulation RNA is converted into electrochemical signals.
Free for circulation RNA information is sent in intelligent mobile terminal equipment 22 by the 3rd wireless communication module 215 by controller 211.Intelligent mobile terminal equipment 22 carries out remote storage and analysis to the free RNA information of circulation.
Intelligent terminal 22 can be smart mobile phone, flat board or computer.
Data receiver 12 can be worn on any part of cancer patient's health, such as wrist.
First wireless communication module 13, second wireless communication module 214, the 3rd wireless communication module 215 adopt Bluetooth protocol.
Siren 213 is vibrators, notifies that wearer notes the danger of cancer return by the mode of vibration.
The free RNA sensor 11 of circulation comprises circulation free RNA trapping layer 111, hybridization signal inductive layer 112.The free RNA trapping layer 111 of circulation is made up of the capture probe with the free RNA specific binding of circulation.Capture probe is peptide nucleic acid(PNA) (PNA).
Hybridization signal inductive layer 112 comprises silicon nanowire array and forms.Hybridization signal inductive layer 112 is on the silicon nanowires utilizing conventional semiconductors technology to process, and is prepared from by silylation modification, surperficial unimolecule rete self assembly operation, fixes to form the free RNA sensor of circulation through capture probe.The preparation process of the free RNA sensor of circulation is well known to those skilled in the art.
Controller 211 timing realizes the free unlatching of RNA sensor of circulation or the control of dormancy.The interval time of continuously adjustabe between 1s to 1800s that control command is assigned, adjustment stepping is 2s.
Circulation in the present embodiment RNA that dissociates refers to circulating tumor miRNA.
The using method of above-mentioned implanted cancer return real-time monitoring system:
1, control implanted cancer return real-time monitoring system by controller 211 and be in resting state, et al. Ke assembly, with negative electricity (institute is electrically charged atomic weak, can not damage human body), is implanted subcutaneous by the free RNA sensor 11 of now circulation;
2, open implanted cancer return real-time monitoring system by controller 211, make the circulation RNA sensor 11 that dissociates not charged, the RNA that dissociates of the circulation now in tissue fluid can be combined with the free RNA sensor 11 of circulation;
3, after reacting certain hour, close implanted cancer return real-time monitoring system by controller 211 to make it again to be in resting state, the free RNA sensor 11 of now circulation is with negative electricity, the circulation combined with circulation free RNA sensor 11 in tissue fluid RNA and the circulation RNA sensor 11 that dissociates that dissociates is separated, and implanted cancer return real-time monitoring system is that detection is next time ready.
Whether 4, vibrated by the dissociate RNA information or intelligent mobile terminal equipment 22 and siren 213 of circulation of display on observation display 212, cancer patient knows whether cancer recurs.
Embodiment 4 one kinds of implanted cancer return real-time monitoring systems
A kind of implanted cancer return real-time monitoring system, cancer return real-time monitoring system comprises et al. Ke assembly 1 and external assembly 2, et al. Ke assembly 1 comprises circulation free RNA sensor 11, data processing module 12, first wireless communication module 13, data processing module 12 comprises input interface 121, microprocessor 122, output interface 123, reactor 124, input interface 121 receives electrochemical signals that the free RNA sensor 11 of circulation exports and input microprocessor 122 after it being converted into digital signal, is uploaded to external assembly 2 after microprocessor 122 pairs of digital signals carry out protocol conversion by output interface 123 via the first wireless communication module 13, external assembly 2 comprises data receiver 21, intelligent mobile terminal equipment 22, data receiver 21 comprises controller 211, display 212, siren 213, second wireless communication module 214, the 3rd wireless communication module 215, controller 211 receives and analyzing body is implanted into circulation that assembly 1 uploads dissociates RNA signal, afterwards free for circulation RNA information is sent on display and shows, the analysis programme of controller 211 arranges a threshold value, when this threshold value of horizontal exceeding of the free RNA that circulates, controller 211 sends instruction to described siren 213, siren 213 gives the alarm, notify that wearer notes the danger of cancer return, the control command of controller 211 passes on the reactor 124 in et al. Ke assembly 1 by the second wireless communication module 214, reactor 124 controlled circulation dissociates the unlatching of RNA sensor 11 or resting state, when dissociating 11 dormancy of RNA sensor when circulating, the free RNA sensor of circulation is with negative electricity, association reaction is there is not with the RNA that dissociates of the circulation with negative electricity, when the free RNA sensor 11 that circulates is opened, the free RNA sensor of circulation is not charged, association reaction is there is with the RNA that dissociates of the circulation with negative electricity, electronegative circulation RNA cause the circulating electrical conductivity of free RNA sensor of dissociating changes, thus the concentration information of free for circulation RNA is converted into electrochemical signals.
Free for circulation RNA information is sent in intelligent mobile terminal equipment 22 by the 3rd wireless communication module 215 by controller 211.Intelligent mobile terminal equipment 22 carries out remote storage and analysis to the free RNA information of circulation.
Intelligent terminal 22 can be smart mobile phone, flat board or computer.
Data receiver 12 uses as in vitro accessory.
First wireless communication module 13, second wireless communication module 214, the 3rd wireless communication module 215 adopt Zigbee protocol.
Siren 213 is luminous organs, notifies that wearer notes the danger of cancer return by the mode of luminescence.
The free RNA sensor 11 of circulation comprises circulation free RNA trapping layer 111, hybridization signal inductive layer 112.The free RNA trapping layer 111 of circulation is made up of the capture probe with the free RNA specific binding of circulation.Capture probe is peptide nucleic acid(PNA) (PNA).
Hybridization signal inductive layer 112 comprises silicon nanowire array.Hybridization signal inductive layer 112 is on the silicon nanowires utilizing conventional semiconductors technology to process, and is prepared from by silylation modification, surperficial unimolecule rete self assembly operation, fixes to form the free RNA sensor 11 of circulation through capture probe.The preparation process of the free RNA sensor 11 of circulation is well known to those skilled in the art.
Controller 211 timing realizes the free unlatching of RNA sensor 11 of circulation or the control of dormancy.The interval time of continuously adjustabe between 1s to 1800s that control command is assigned, adjustment stepping is 2s.
Circulation in the present embodiment RNA that dissociates refers to circulation free mRNA.
The using method of above-mentioned implanted cancer return real-time monitoring system:
1, control implanted cancer return real-time monitoring system by controller 211 and be in resting state, et al. Ke assembly, with negative electricity (institute is electrically charged atomic weak, can not damage human body), is implanted subcutaneous by the free RNA sensor 11 of now circulation;
2, open implanted cancer return real-time monitoring system by controller 211, make the circulation RNA sensor 11 that dissociates not charged, the RNA that dissociates of the circulation now in tissue fluid can be combined with the free RNA sensor 11 of circulation;
3, after reacting certain hour, close implanted cancer return real-time monitoring system by controller 211 to make it again to be in resting state, the free RNA sensor 11 of now circulation is with negative electricity, the circulation combined with circulation free RNA sensor 11 in tissue fluid RNA and the circulation RNA sensor 11 that dissociates that dissociates is separated, and implanted cancer return real-time monitoring system is that detection is next time ready.
Whether 4, luminous by the dissociate RNA information or intelligent mobile terminal equipment 22 and siren 213 of circulation of display on observation display 212, cancer patient knows whether cancer recurs.
Although illustrate and describe embodiments of the invention, those having ordinary skill in the art will appreciate that: can carry out multiple change, amendment, replacement and modification to these embodiments when not departing from principle of the present invention and aim, scope of the present invention is by claim and equivalents thereof.
Claims (9)
1. an implanted cancer return real-time monitoring system, is characterized in that, described monitoring system comprises et al. Ke assembly (1) and external assembly (2), described et al. Ke assembly (1) comprises circulation free RNA sensor (11), data processing module (12), the first wireless communication module (13), described data processing module (12) comprises input interface (121), microprocessor (122), output interface (123), reactor (124), described input interface (121) receives described circulation and to dissociate electrochemical signals that RNA sensor (11) exports input described microprocessor (122) after it is converted into digital signal, is uploaded to described external assembly (2) after described microprocessor (122) carries out protocol conversion to digital signal by described output interface (123) via described first wireless communication module (13), described external assembly (2) comprises data receiver (21), and described data receiver (21) comprises controller (211), display (212), siren (213), the second wireless communication module (214), described controller (211) receives and analyzes circulation that described et al. Ke assembly (1) uploads and to dissociate RNA signal, afterwards free for circulation RNA information is sent to the upper display of described display (212), the analysis programme of described controller (211) arranges a threshold value, when this threshold value of horizontal exceeding of the free RNA that circulates, described controller (211) sends instruction to described siren (213), described siren (213) gives the alarm, notify that wearer notes the danger of cancer return, the control command of described controller (211) passes on the described reactor (124) in described et al. Ke assembly (1) by described second wireless communication module (214), control described circulation to dissociate the unlatching of RNA sensor (11) or resting state, when described circulation dissociates RNA sensor (11) dormancy, the free RNA sensor (11) of circulation is with negative electricity, association reaction is there is not with the RNA that dissociates of the circulation with negative electricity, when described circulation dissociates RNA sensor (11) unlatching, the described circulation RNA sensor (11) that dissociates is not charged, association reaction is there is with the RNA that dissociates of the circulation with negative electricity, the electronegative circulation RNA that dissociates causes the dissociate electrical conductivity of RNA sensor (11) of described circulation to change, thus the concentration information of free for circulation RNA is converted into electrochemical signals.
2. monitoring system according to claim 1, it is characterized in that, described external assembly (2) also comprises intelligent mobile terminal equipment (22), described data receiver (21) also comprises the 3rd wireless communication module (215), and free for circulation RNA information is sent in described intelligent mobile terminal equipment (22) by described 3rd wireless communication module (215) by described controller (211).
3. monitoring system according to claim 1 and 2, is characterized in that, described siren (213) is vibrator, notifies that wearer notes the danger of cancer return by the mode of vibration.
4. monitoring system according to claim 1 and 2, is characterized in that, described siren (213) is luminous organ, notifies that wearer notes the danger of cancer return by the mode of luminescence.
5. monitoring system according to claim 1 and 2, is characterized in that, the described circulation RNA sensor (11) that dissociates comprises circulation free RNA trapping layer (111), hybridization signal inductive layer (112); Described circulation RNA trapping layer (111) of dissociating sticks on described hybridization signal inductive layer (112).
6. monitoring system according to claim 5, is characterized in that, described circulation RNA trapping layer (111) of dissociating is made up of the capture probe with the free RNA specific binding of circulation.
7. monitoring system according to claim 6, is characterized in that, described capture probe is peptide nucleic acid(PNA).
8. monitoring system according to claim 5, is characterized in that, described hybridization signal inductive layer (112) comprises silicon nanowire array.
9. monitoring system according to claim 1 and 2, it is characterized in that, described first wireless communication module (13), described second wireless communication module (214), described 3rd wireless communication module (215) adopt in Bluetooth protocol or Zigbee protocol any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510406415.3A CN104939843B (en) | 2015-07-12 | 2015-07-12 | Implanted cancer relapse real-time monitoring system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510406415.3A CN104939843B (en) | 2015-07-12 | 2015-07-12 | Implanted cancer relapse real-time monitoring system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104939843A true CN104939843A (en) | 2015-09-30 |
| CN104939843B CN104939843B (en) | 2017-05-17 |
Family
ID=54155323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510406415.3A Active CN104939843B (en) | 2015-07-12 | 2015-07-12 | Implanted cancer relapse real-time monitoring system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104939843B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111132604A (en) * | 2017-09-13 | 2020-05-08 | 豪洛捷公司 | Wireless active monitoring implant system |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100268199A1 (en) * | 2009-02-25 | 2010-10-21 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device for passively removing a target component from blood or lymph of a vertebrate subject |
| CN101869468A (en) * | 2010-06-21 | 2010-10-27 | 黄爱强 | Monitoring system for human tumor recurrence and metastasis |
| US20130018243A1 (en) * | 2011-07-13 | 2013-01-17 | Lockheed Martin Corporation | Three dimensional microfluidic multiplexed diagnostic system |
| US20130158378A1 (en) * | 2011-09-22 | 2013-06-20 | The Ohio State University | Ionic barrier for floating gate in vivo biosensors |
| CN103932680A (en) * | 2014-04-15 | 2014-07-23 | 广州玖玖伍捌信息科技有限公司 | Human body tumor recurrence monitoring and thermal therapy integrated system |
-
2015
- 2015-07-12 CN CN201510406415.3A patent/CN104939843B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100268199A1 (en) * | 2009-02-25 | 2010-10-21 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device for passively removing a target component from blood or lymph of a vertebrate subject |
| CN101869468A (en) * | 2010-06-21 | 2010-10-27 | 黄爱强 | Monitoring system for human tumor recurrence and metastasis |
| US20130018243A1 (en) * | 2011-07-13 | 2013-01-17 | Lockheed Martin Corporation | Three dimensional microfluidic multiplexed diagnostic system |
| US20130158378A1 (en) * | 2011-09-22 | 2013-06-20 | The Ohio State University | Ionic barrier for floating gate in vivo biosensors |
| CN103932680A (en) * | 2014-04-15 | 2014-07-23 | 广州玖玖伍捌信息科技有限公司 | Human body tumor recurrence monitoring and thermal therapy integrated system |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111132604A (en) * | 2017-09-13 | 2020-05-08 | 豪洛捷公司 | Wireless active monitoring implant system |
| CN111132604B (en) * | 2017-09-13 | 2023-04-04 | 豪洛捷公司 | Wireless active monitoring implant system |
| US11877857B2 (en) | 2017-09-13 | 2024-01-23 | Hologic, Inc. | Wireless active monitoring implant system |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104939843B (en) | 2017-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tripathi et al. | The physics of cellular decision making during epithelial–mesenchymal transition | |
| CN109996888A (en) | For testing and analyzing the method and composition of object | |
| Valls-Margarit et al. | Engineered macroscale cardiac constructs elicit human myocardial tissue-like functionality | |
| Ghobadi et al. | Regenerative potential of endometrial stem cells: a mini review | |
| CN1700879A (en) | Healthcare monitoring system | |
| CN109655512A (en) | A kind of excretion body detecting method based on aptamers and rolling circle amplification | |
| CN103409427A (en) | Aptamer Ep CAM C of epithelial cell adhesion molecule, and preparation method of same | |
| Tetzlaff et al. | Epstein‐Barr virus‐associated leiomyosarcoma with cutaneous involvement in an African child with human immunodeficiency virus: a case report and review of the literature | |
| Cai et al. | Primary cilia are sensors of electrical field stimulation to induce osteogenesis of human adipose-derived stem cells | |
| Mali et al. | Characterization of human dermal papilla cells in alginate spheres | |
| Ai et al. | microRNA-196a promotes osteogenic differentiation and inhibit adipogenic differentiation of adipose stem cells via regulating β-catenin pathway | |
| Cunha et al. | Machine learning for stem cell differentiation and proliferation classification on electrical impedance spectroscopy | |
| CN104939843A (en) | Implanted cancer relapse real-time monitoring system | |
| Garg et al. | Latest advances on MXenes in biomedical research and health care | |
| Šafaříková et al. | Conductive polymer PEDOT: PSS-based platform for embryonic stem-cell differentiation | |
| CN204813902U (en) | Implanted cancer recurring real -time monitoring system | |
| Stewart et al. | Bioelectricity and epimorphic regeneration | |
| Min et al. | Biphasic electrical pulse by a micropillar electrode array enhances maturation and drug response of reprogrammed cardiac spheroids | |
| Carrara et al. | Remote system for monitoring animal models with single-metabolite bio-nano-sensors | |
| CN107149524A (en) | Intelligent sanitary sliver | |
| Moya-Ramírez et al. | Polymer encapsulation of bacterial biosensors enables coculture with mammalian cells | |
| CN113684130A (en) | Equipment and method for stimulating secretion of cell exosome, obtained exosome and application thereof | |
| WO2004094610A3 (en) | Wnt as a factor for cardiac myogenesis | |
| Gallego-Valle et al. | Ectopic FOXP3 expression in combination with TGF-β1 and IL-2 stimulation generates limited suppressive function in human primary activated thymocytes ex vivo | |
| CN204813901U (en) | A smart machine for monitoring of cancer recurring real time kinematic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Implanted cancer relapse real-time monitoring system Effective date of registration: 20171212 Granted publication date: 20170517 Pledgee: Huaxia Bank Beijing branch Wanliu Limited by Share Ltd Pledgor: Beijing Yang Shen biology information technology company limited Registration number: 2017990001155 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20181206 Granted publication date: 20170517 Pledgee: Huaxia Bank Beijing branch Wanliu Limited by Share Ltd Pledgor: Beijing Yang Shen biology information technology company limited Registration number: 2017990001155 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Implanted cancer relapse real-time monitoring system Effective date of registration: 20181225 Granted publication date: 20170517 Pledgee: Huaxia Bank Beijing branch Wanliu Limited by Share Ltd Pledgor: Beijing Yang Shen biology information technology company limited Registration number: 2018990001252 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20191206 Granted publication date: 20170517 Pledgee: Huaxia Bank Beijing branch Wanliu Limited by Share Ltd Pledgor: Beijing Yang Shen biology information technology company limited Registration number: 2018990001252 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200228 Address after: Room 2503, Qianshan building, building D2, Qingdao International Innovation Park Phase II, No. 1, Keyuan Weiyi Road, Laoshan District, Qingdao, Shandong Province Patentee after: Qingdao Yangshen biomedical Co., Ltd Address before: The court building 1 cubic Beijing No. 100080 Haidian District Shanyuan street 3103 Patentee before: Beijing Yang Shen biology information technology company limited |